D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 74 Citations 29,572 233 World Ranking 12585 National Ranking 254

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

His scientific interests lie mostly in Hemophagocytic lymphohistiocytosis, Immunology, Familial Hemophagocytic Lymphohistiocytosis, UNC13D and Pediatrics. His work carried out in the field of Hemophagocytic lymphohistiocytosis brings together such families of science as Gastroenterology, Reactive Hemophagocytic Syndrome, Hemophagocytosis and Macrophage activation syndrome. The study incorporates disciplines such as Cytotoxic T cell and Histiocytosis, Disease, Pathology in addition to Immunology.

In his work, Hepatosplenomegaly is strongly intertwined with Cytopenia, which is a subfield of UNC13D. The concepts of his Pediatrics study are interwoven with issues in Cancer, Hematopoietic stem cell transplantation, Hyponatremia, Treatment protocol and Rash. His research in the fields of Etoposide overlaps with other disciplines such as In patient.

His most cited work include:

  • HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. (2671 citations)
  • Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis (990 citations)
  • Contemporary classification of histiocytic disorders (689 citations)

What are the main themes of his work throughout his whole career to date?

Jan-Inge Henter focuses on Immunology, Hemophagocytic lymphohistiocytosis, Pediatrics, Internal medicine and Langerhans cell histiocytosis. In his study, Cancer research is inextricably linked to Cytotoxic T cell, which falls within the broad field of Immunology. His Hemophagocytic lymphohistiocytosis research is multidisciplinary, relying on both Hematopoietic stem cell transplantation, Transplantation, Etoposide, Macrophage activation syndrome and UNC13D.

As a part of the same scientific study, Jan-Inge Henter usually deals with the Pediatrics, concentrating on Disease and frequently concerns with Etiology. His biological study spans a wide range of topics, including Gastroenterology, Surgery and Oncology. Jan-Inge Henter has included themes like Langerhans cell, Histiocytosis and Interleukin 17 in his Langerhans cell histiocytosis study.

He most often published in these fields:

  • Immunology (46.04%)
  • Hemophagocytic lymphohistiocytosis (32.37%)
  • Pediatrics (25.54%)

What were the highlights of his more recent work (between 2017-2021)?

  • Immunology (46.04%)
  • Hemophagocytic lymphohistiocytosis (32.37%)
  • Langerhans cell histiocytosis (18.71%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Immunology, Hemophagocytic lymphohistiocytosis, Langerhans cell histiocytosis, Internal medicine and Cancer research. The concepts of his Immunology study are interwoven with issues in Phenotype, Disease and Coronavirus disease 2019. His study in Hemophagocytic lymphohistiocytosis is interdisciplinary in nature, drawing from both Hematopoietic stem cell transplantation, Etoposide, Multiple organ dysfunction syndrome, Pediatrics and UNC13D.

The study incorporates disciplines such as Histiocyte and Familial Hemophagocytic Lymphohistiocytosis in addition to Etoposide. Jan-Inge Henter interconnects Salvage therapy and Dexamethasone in the investigation of issues within Familial Hemophagocytic Lymphohistiocytosis. His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Sepsis.

Between 2017 and 2021, his most popular works were:

  • Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. (477 citations)
  • Recommendations for the management of hemophagocytic lymphohistiocytosis in adults (185 citations)
  • Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. (39 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Jan-Inge Henter spends much of his time researching Hemophagocytic lymphohistiocytosis, Immunology, Internal medicine, Immune system and Multiple organ dysfunction syndrome. His studies in Hemophagocytic lymphohistiocytosis integrate themes in fields like Histiocyte, Etoposide, Odds ratio and Late onset. His study looks at the relationship between Histiocyte and topics such as Pediatrics, which overlap with Cancer.

His Etoposide research is multidisciplinary, relying on both Salvage therapy, Intensive care medicine, Familial Hemophagocytic Lymphohistiocytosis and Dosing. His Immunology research is multidisciplinary, incorporating elements of Phenotype and Coronavirus disease 2019. His work on Cytarabine, Hematology and Gemcitabine as part of general Internal medicine study is frequently connected to SAMHD1, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Jan-Inge Henter;Annacarin Horne;Maurizio Aricó;R Maarten Egeler.
Pediatric Blood & Cancer (2007)

4173 Citations

Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis

Susan E. Stepp;Rémi Dufourcq-Lagelouse;Françoise Le Deist;Françoise Le Deist;Sadhna Bhawan.
Science (1999)

1366 Citations

Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society.

Jan-Inge Henter;Göran Elinder;Åke Öst.
Seminars in Oncology (1991)

1037 Citations

Contemporary classification of histiocytic disorders

Blaise E. Favara;Alfred C. Feller;Macro Pauli;Elaine S. Jaffe.
Medical and Pediatric Oncology (1997)

1029 Citations

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

Jan-Inge Henter;AnnaCarin Samuelsson-Horne;Maurizio Aricò;R Maarten Egeler.
Blood (2002)

854 Citations

Hypercytokinemia in Familial Hemophagocytic Lymphohistiocytosis

Jan-Inge Henter;Göran Elinder;Olle Söder;Mona Hansson.
Blood (1991)

604 Citations

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.

Takuya Sekine;André Perez-Potti;Olga Rivera-Ballesteros;Kristoffer Strålin.
Cell (2020)

587 Citations

Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11

Udo zur Stadt;Susanne Schmidt;Brigitte Kasper;Karin Beutel.
Human Molecular Genetics (2005)

587 Citations

INFECTION- AND MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC SYNDROMES Secondary Hemophagocytic Lymphohistiocytosis

Gritta Janka;Shinsaku Imashuku;Göran Elinder;Marion Schneider.
Hematology-oncology Clinics of North America (1998)

571 Citations

Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society.

Aricò M;Janka G;Fischer A;Henter Ji.
Leukemia (1996)

551 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jan-Inge Henter

Gunnar Steineck

Gunnar Steineck

University of Gothenburg

Publications: 97

Joseph A. Trapani

Joseph A. Trapani

Peter MacCallum Cancer Centre

Publications: 89

Yenan T. Bryceson

Yenan T. Bryceson

University of Bergen

Publications: 71

Geneviève de Saint Basile

Geneviève de Saint Basile

Necker-Enfants Malades Hospital

Publications: 64

Ilia Voskoboinik

Ilia Voskoboinik

Peter MacCallum Cancer Centre

Publications: 64

Alain Fischer

Alain Fischer

Collège de France

Publications: 61

Bengt Fadeel

Bengt Fadeel

Karolinska Institute

Publications: 57

Nima Rezaei

Nima Rezaei

Tehran University of Medical Sciences

Publications: 56

Maurizio Aricò

Maurizio Aricò

Boston Children's Hospital

Publications: 56

Stephan Ehl

Stephan Ehl

University of Freiburg

Publications: 55

Angelo Ravelli

Angelo Ravelli

Istituto Giannina Gaslini

Publications: 48

Alexandra H. Filipovich

Alexandra H. Filipovich

Cincinnati Children's Hospital Medical Center

Publications: 48

Michael B. Jordan

Michael B. Jordan

Cincinnati Children's Hospital Medical Center

Publications: 45

Jean-François Emile

Jean-François Emile

University of Paris-Saclay

Publications: 38

Karl Welte

Karl Welte

Boston Children's Hospital

Publications: 38

Gillian M. Griffiths

Gillian M. Griffiths

University of Cambridge

Publications: 35

Trending Scientists

Andre Scedrov

Andre Scedrov

University of Pennsylvania

Robert H. Dennard

Robert H. Dennard

IBM (United States)

Tetsuya Kawanishi

Tetsuya Kawanishi

Waseda University

Yukio Hinatsu

Yukio Hinatsu

Hokkaido University

Masahiro Yoshimura

Masahiro Yoshimura

Tokyo Institute of Technology

David S. Latchman

David S. Latchman

University College London

Xavier Turon

Xavier Turon

Centro de Estudios Avanzados de Blane

Valerie K. Brown

Valerie K. Brown

CAB International

Patrick J. Stover

Patrick J. Stover

Texas A&M University

Gregory P. Downey

Gregory P. Downey

University of Colorado Denver

Lynda Chin

Lynda Chin

The University of Texas MD Anderson Cancer Center

Bruce J. Richardson

Bruce J. Richardson

City University of Hong Kong

Catherine Lebel

Catherine Lebel

University of Calgary

Dale P. Sandler

Dale P. Sandler

National Institutes of Health

Kaori Togashi

Kaori Togashi

Kyoto University

Linda G. Martin

Linda G. Martin

RAND Corporation

Something went wrong. Please try again later.